Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (GB:0L49)
LSE:0L49
SCYNEXIS (0L49) Share Price & Analysis
0 Followers
0L49 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $3.86
Previous Close$1.5
Volume207.00
Average Volume (3M)1.18K
Market Cap
$58.14M
Enterprise Value-$26.93M
Total Cash (Recent Filing)$88.07M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)N/A
Beta1.80
Next Earnings
May 09, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,753,481
10 Day Avg. Volume0
30 Day Avg. Volume1,175
Standard Deviation0.32
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.63
Price to Sales (P/S)4.29
Price to Cash Flow (P/CF)1.20
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.20
Enterprise Value/Gross Profit-5.29
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$7.17Price Target Upside367.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
SCYNEXIS News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe company's fully enrolled late-stage studies demonstrate a commitment to advancing its pipeline, with SCY-247 showing promising results, potentially leading to new treatment options for patients.
Financial StabilityScynexis's strong financial position is affirmed by a cash runway projection through multiple years, indicating the company's ability to sustain operations and invest in future growth without immediate financial pressures.
Licensing Agreement And FDA ApprovalScynexis reported significant revenue from a licensing deal with GlaxoSmithKline, highlighting the market's confidence in its product, Brexafemme, which also gained FDA approval, ensuring its treatment reach expands.
Bears Say
Clinical Study DelayManufacturing delay/recall has put the MARIO study on hold, impacting timelines.
Financial Agreement RevisionThe deal with GSK was amended due to adjustments in sales milestones related to IBX manufacturing issues.
Product RecallScynexis placed a temporary clinical hold and recalled Brexafemme tablets due to potential cross-contamination issues identified in the manufacturing process.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.53% Other Institutional Investors
99.47% Public Companies and
Individual Investors
0L49 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $1.40 and its highest was $3.85 in the past 12 months.
What is SCYNEXIS’s market cap?
Currently, no data Available
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is May 09, 2024 which is in 10 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Mar 28, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.262.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -$0.18.
How many shares outstanding does SCYNEXIS have?
Currently, no data Available
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went down -2.109%.
Which hedge fund is a major shareholder of SCYNEXIS?
Among the largest hedge funds holding SCYNEXIS’s share is Scion Asset Management. It holds SCYNEXIS’s shares valued at N/A.
---
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.17 (367.10% Upside)
$7.17 (367.10% Upside)
Blogger Sentiment
Bullish
GB:0L49 Sentiment 75%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.66%
12-Months-Change
Fundamentals
Return on Equity
175.97%
Trailing 12-Months
Asset Growth
46.24%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
---
0L49 Company Deck
---
0L49 Earnings Call
Q4 2023
0:00 / 0:00
---
0L49 Stock 12 Months Forecast
Average Price Target
$7.17
▲(367.10% Upside)
Technical Analysis
Best Analysts Covering 0L49
1 Year
1 Year Success Rate
6/36 ratings generated profit
1 Year Average Return
-25.05%
reiterated a buy rating 28 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -25.05% per trade.
---